Drug Profile
MRX 6313
Alternative Names: MRX-6313Latest Information Update: 21 Dec 2021
Price :
$50
*
At a glance
- Originator University of North Carolina at Chapel Hill
- Developer Meryx
- Class Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Receptor protein-tyrosine kinase antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 07 Dec 2021 Meryx has been acquired by Xcovery Holdings
- 28 May 2018 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (PO)
- 28 May 2018 No recent reports of development identified for preclinical development in Solid-tumours in USA (PO)